Impact of angiographic and intravascular ultrasound features on clinical outcome after sirolimus-eluting stent implantation for de-novo lesions in nondiabetic and type 2 diabetic patients

Coronary Artery Disease

Volumn 21, Issue 3, 2010, Pages 175-181

  Du, Run ^a   Zhang, Rui Yan ^a   Zhu, Zheng Bin ^a   Zhang, Qi ^a   Hu, Jian ^a   Yang, Zhen Kun ^a   Yan, Zi Jun ^a   Lv, An Kang ^a   Ding, Feng Hua ^a   Zhang, Jian Sheng ^a   Shen, Wei Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Drug eluting stents; Intimal hyperplasia; Intravascular ultrasound; Sirolimus

Indexed keywords

RAPAMYCIN;

ADULT; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC PATIENT; DISEASE COURSE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REVASCULARIZATION; SURVIVAL RATE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DRUG-ELUTING STENTS; FEMALE; HEART DISEASES; HUMANS; HYPERPLASIA; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 77951298068     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32833811fe     Document Type: Article

References (26)

1. West NE, Ruygrok PN, Disco CM, Webster MW, Lindeboom WK, O'Neill WW, et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004; 109:867-873.
2. Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993; 118:344-349.
3. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40:2082-2089.
4. Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, Gó mez-Hospital JA, Alfonso F, Hernández-Antolín R, et al.; DIABETES Investigators. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimuseluting stent (DIABETES) trial. Circulation 2005; 112:2175-2183.
5. Mulukutla SR, Vlachos HA, Marroquin OC, Selzer F, Holper EM, Abbott JD, et al. Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv 2008; 2:139-147.
6. Ortolani P, Balducelli M, Marzaroli P, Piovaccari G, Menozzi A, Guiducci V, et al. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry. Circulation 2008; 117:923-930.
7. Kumbhani DJ, Bavry AA, Kamdar AR, Helton TJ, Bhatt DL. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials. Am Heart J 2008; 155:640-647.
8. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 2006; 113:414-419.
9. Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Costa MA, Alfonso F, Gó mez-Hospital JA, et al.; DIABETES Investigators. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: threedimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol 2006; 47:2172-2179.
10. Iijima R, Ndrepepa G, Mehilli J, Markwardt C, Bruskina O, Pache J, et al. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 2007; 154:688-693.
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
12. Berry C, L'Allier PL, Gré goire J, Lespé rance J, Levesque S, Ibrahim R, et al. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation 2007; 115:1851-1857.
13. Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A, et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation 2003; 108:2747-2750.
14. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials. A case for standardized definitions. Circulation 2007; 115:2344-2351.
15. Tsuchida K, Garcia-Garcia HM, Ong AT, Valgimigli M, Aoki J, Rademaker TA, et al. Revisiting late loss and neointimal volumetric measurements in a drugeluting stent trial: analysis from the SPIRIT FIRST trial. Catheter Cardiovasc Interv 2006; 67:188-197.
16. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (ran-domized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions) trial. Circulation 2002; 106:798-803.
17. Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, et al.; Ravel Investigators. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur Heart J 2004; 25:107-112.
18. Kimura M, Mintz GS, Weissman NJ, Dawkins KD, Grube E, Ellis SG, et al. Meta-analysis of the effects of paclitaxel-eluting stents versus bare metal stents on volumetric intravascular ultrasound in patients with versus without diabetes mellitus. Am J Cardiol 2008; 101:1263-1268.
19. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115:2426-2434.
20. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, et al. Incidence, mechanism predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation 2004; 109:881-886.
21. Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek W, et al. TAXUS II Study Group. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation 2005; 111:900-905.
22. Nicholls SJ, Tuzcu EM, Kalidindi S,Wolski K, Moon KW, Sipahi I, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008; 52:255-262.
23. Jensen LO, Thayssen P, Mintz GS, Maeng M, Junker A, Galloe A, et al. Intravascular ultrasound assessment of remodelling and reference segment plaque burden in type-2 diabetic patients. Eur Heart J 2007; 28:1759-1764.
24. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA,Wong SC, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005; 45:1172-1179.
25. Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Alfonso F, Hernández-Antolín R, SanMartín M, et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 2007; 28:1946-1952.
26. Mathew V, Gersh BJ,Williams BA, Laskey WK,Willerson JT, Tilbury RT, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the prevention of restenosis with tranilast and its outcomes (PRESTO) Trial. Circulation 2004; 109:476-480.